Molecular and Clinical Hematology Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Mol Ther. 2012 Oct;20(10):1882-92. doi: 10.1038/mt.2012.159. Epub 2012 Aug 7.
Human immunodeficiency virus type 1 (HIV1) vectors poorly transduce rhesus hematopoietic cells due to species-specific restriction factors, including the tripartite motif-containing 5 isoformα (TRIM5α) which targets the HIV1 capsid. We previously developed a chimeric HIV1 (χHIV) vector system wherein the vector genome is packaged with the simian immunodeficiency virus (SIV) capsid for efficient transduction of both rhesus and human CD34(+) cells. To evaluate whether χHIV vectors could efficiently transduce rhesus hematopoietic repopulating cells, we performed a competitive repopulation assay in rhesus macaques, in which half of the CD34(+) cells were transduced with standard SIV vectors and the other half with χHIV vectors. As compared with SIV vectors, χHIV vectors achieved higher vector integration, and the transgene expression rates were two- to threefold higher in granulocytes and red blood cells and equivalent in lymphocytes and platelets for 2 years. A recipient of χHIV vector-only transduced cells reached up to 40% of transgene expression rates in granulocytes and lymphocytes and 20% in red blood cells. Similar to HIV1 and SIV vectors, χHIV vector frequently integrated into gene regions, especially into introns. In summary, our χHIV vector demonstrated efficient transduction for rhesus long-term repopulating cells, comparable with SIV vectors. This χHIV vector should allow preclinical testing of HIV1-based therapeutic vectors in large animal models.
人类免疫缺陷病毒 1 型(HIV1)载体由于物种特异性限制因子,如包含三部分基序的 5 型异构体α(TRIM5α),对 HIV1 衣壳具有靶向作用,因此对恒河猴造血细胞的转导效率较低。我们之前开发了一种嵌合 HIV1(χHIV)载体系统,其中载体基因组与猿猴免疫缺陷病毒(SIV)衣壳包装在一起,可有效转导恒河猴和人类 CD34(+)细胞。为了评估 χHIV 载体是否能有效转导恒河猴造血重建细胞,我们在恒河猴中进行了竞争重建实验,其中一半的 CD34(+)细胞用标准 SIV 载体转导,另一半用 χHIV 载体转导。与 SIV 载体相比,χHIV 载体实现了更高的载体整合,在粒细胞和红细胞中转基因表达率提高了两到三倍,在淋巴细胞和血小板中转基因表达率相同,持续了 2 年。仅接受 χHIV 载体转导的细胞的受体在粒细胞和淋巴细胞中的转基因表达率高达 40%,在红细胞中的转基因表达率高达 20%。与 HIV1 和 SIV 载体类似,χHIV 载体经常整合到基因区域,特别是整合到内含子中。总之,我们的 χHIV 载体在恒河猴长期重建细胞中表现出高效的转导效率,与 SIV 载体相当。这种 χHIV 载体应该允许在大动物模型中对基于 HIV1 的治疗性载体进行临床前测试。